EDX Medical Group PLC
LLSE:EDX8.50
GBX
0.00
(0.00%)
ISIN
GB00BNDMJS47
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
GBP
•
in mil. unless spec.Working Capital
GBP
•
in mil. unless spec.Growth Rates
GBP
•
in mil. unless spec.Semi-annual Revenue
GBP
•
in mil. unless spec.Semi-annual Earnings Per Share
GBP
•
in mil. unless spec.Semi-annual Dividends Per Share
GBP
•
in mil. unless spec.Company Description
- CEO
- Michael John Hudson
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Cambridge United Kingdom
- Website
- edxmedical.co.uk
- Similar Companies
- Business
- EDX Medical Group PLC operates as a biotechnology and healthcare diagnostics company specializing in the development, validation, and commercialization of innovative digital diagnostic products, molecular testing, and precision medicine solutions. Founded in 2022 and headquartered at Cambridge Science Park in Cambridge, United Kingdom, the company focuses on early disease detection, disease risk prediction, and personalized treatment management across oncology, cardiology, neurology, and infectious diseases. EDX Medical Group operates an ISO 15189-accredited molecular biology and diagnostics laboratory in Cambridge, providing high-throughput genomic sequencing, molecular assay development, clinical testing, and quality assurance services to healthcare professionals, clinical research organizations, hospitals, and corporate clients primarily across the United Kingdom and Europe. The company's product and service portfolio encompasses advanced cancer diagnostic platforms, proprietary multi-target diagnostic assays, point-of-care rapid testing technologies, and corporate health management services. Its diagnostic and clinical testing offerings include proprietary Super Tests for high-sensitivity early detection and risk stratification of specific malignancies, including prostate cancer, bowel cancer, and testicular cancer; comprehensive tumor genomic profiling platforms distributed in partnership with Caris Life Sciences, including MI Profile, MI Tumor Seek, and Caris Assure liquid biopsy solutions; functional oncology assessment platforms, including Curesponse cResponse, designed to evaluate tumor tissue sensitivity to chemotherapies, immunotherapies, and targeted biologics; proprietary diagnostic assays and intellectual property in-licensed for chemotherapy toxicity and dosage management, such as 5-fluorouracil monitoring; rapid point-of-care infectious disease diagnostics and microfluidic testing platforms developed through its subsidiaries; and bespoke corporate employee health and preventative wellness screening programs. The company operates through wholly owned subsidiaries, including Torax Biosciences Ltd, which specializes in diagnostic reagent development and assay formulation, and Hutano Diagnostics Ltd, which focuses on point-of-care biosensor diagnostics. In recent developments, EDX Medical Group has accelerated its commercialization strategy and clinical testing pipeline through key strategic partnerships, product launches, and capital market transactions. The company expanded its oncology portfolio with the commercial rollout of its TC100 testicular cancer testing service, an advanced early-stage bowel cancer screening service, and the integration of Mainz BioMed cancer diagnostic technologies. To enhance its clinical research and diagnostic capabilities, EDX Medical established a multi-stakeholder collaboration with the University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, and the UK Health Security Agency to develop advanced diagnostic tests for hospital-acquired pneumonia in critically ill patients, alongside an ongoing assay co-development collaboration with Thermo Fisher Scientific. Additionally, the company entered into a diagnostic exploration partnership with Spire Healthcare and secured a multi-year corporate wellbeing screening agreement with Arnold Clark Group. Structurally and financially, EDX Medical Group completed equity fundraising rounds and convertible debt placements to support laboratory expansion, advanced its corporate presence on UK public markets with a transition from the Aquis Growth Market to the London Stock Exchange AIM market, and continues to expand its intellectual property assets through licensing agreements with academic institutions including Oxford University Innovation.